Longeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor
Longeveron Inc. (LGVN) said CFO Lisa Locklear will step down, and Marie Washburn will become CFO effective July 13. Longeveron is preparing for Phase 2b Phase 2b laromestrocel results for Hypoplastic Left Heart Syndrome in Q3 2026. LGVN closed at $0.6495, down 5.94%, and fell further in after-hours.
How this was made
The 30-second read
Why it matters
The CFO transition could influence investor confidence in finance/operations, but the article’s only concrete fundamental timeline is the expected Q3 2026 trial top-line.
Market read
Near-term trading interest is likely limited to succession-related sentiment; the larger catalyst is the upcoming Phase 2b top-line window.
What to watch
Traders may be over-weighting the executive transition versus the lack of new clinical or financial disclosures; the real driver remains the Q3 2026 laromestrocel readout.
Background
Longeveron is a clinical-stage biotech preparing for Phase 2b top-line results for laromestrocel in Hypoplastic Left Heart Syndrome.
Ticker impact
Longeveron announced CFO Lisa Locklear’s departure and named Marie Washburn as CFO effective July 13, alongside Phase 2b laromestrocel timing into Q3 2026.
Likely modest near-term volatility around the CFO change, with more meaningful repricing risk as Q3 2026 trial top-line approaches.
The article provides a concrete executive change date and reiterates the trial readout window, but it does not include new trial results, guidance, financing, or regulatory outcomes.
Market effects
Biotech governance/leadership changes can affect perceived execution risk, but no sector-wide read-across is provided here.
No specific regional market linkage beyond Nasdaq-listed small-cap biotech sentiment.
No global macro or cross-border transaction details disclosed.
Counterpoint
The CFO change may be routine succession planning and may not materially affect the probability/timing of Phase 2b top-line results.
Key entities
- companyLongeveron Inc.
Nasdaq-listed clinical-stage biotech; announced CFO transition and reiterated Phase 2b top-line timing.
- personLisa Locklear
CFO stepping down; will pursue board opportunities and other interests.
- personMarie Washburn
Appointed Senior Vice President and CFO effective July 13; previously corporate controller since Nov 2025.
- assetlaromestrocel
Phase 2b investigational treatment; top-line results expected in Q3 2026.
